Cargando…
Anti-CD45 Radioimmunotherapy with (90)Y but Not (177)Lu Is Effective Treatment in a Syngeneic Murine Leukemia Model
Radioimmunotherapy (RIT) for treatment of hematologic malignancies has primarily employed monoclonal antibodies (Ab) labeled with (131)I or (90)Y which have limitations, and alternative radionuclides are needed to facilitate wider adoption of RIT. We therefore compared the relative therapeutic effic...
Autores principales: | Orozco, Johnnie J., Balkin, Ethan R., Gooley, Ted A., Kenoyer, Aimee, Hamlin, Donald K., Wilbur, D. Scott, Fisher, Darrell R., Hylarides, Mark D., Shadman, Mazyar, Green, Damian J., Gopal, Ajay K., Press, Oliver W., Pagel, John M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4252056/ https://www.ncbi.nlm.nih.gov/pubmed/25460570 http://dx.doi.org/10.1371/journal.pone.0113601 |
Ejemplares similares
-
Comparative Efficacy of (177)Lu and (90)Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models
por: Frost, Sofia H. L., et al.
Publicado: (2015) -
In vitro characterisation of [(177)Lu]Lu-DOTA-C595 as a novel radioimmunotherapy for MUC1-CE positive pancreatic cancer
por: Hull, Ashleigh, et al.
Publicado: (2023) -
Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021) -
(177)Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer
por: Hernandez, Reinier, et al.
Publicado: (2020) -
First clinical experience with fractionated intracavitary radioimmunotherapy using [(177)Lu]Lu-6A10-Fab fragments in patients with glioblastoma: a pilot study
por: Roll, Wolfgang, et al.
Publicado: (2023)